Tyra Biosciences

Tyra Biosciences is a biotechnology company headquartered in Carlsbad, California, in the United States. According to its official website, the company describes itself as developing "Next-Generation Precision Molecules" and is focused on advancing clinical studies of an oral drug candidate called dabogratinib. The company's stated therapeutic areas for this candidate are skeletal dysplasia and urologic cancers. The company presents itself as a precision-medicine developer, meaning it aims to design molecules that target specific biological pathways or genetic drivers of disease rather than broad, non-selective treatments. Its lead clinical program, oral dabogratinib, is being studied in two distinct areas: skeletal dysplasia, a group of rare genetic disorders affecting bone and cartilage development, and urologic cancers, which include malignancies of the urinary tract and related organs. Tyra Biosciences maintains a public-facing presence at tyra.bio, where it invites interested parties to sign up for updates on its clinical studies. The website emphasizes the company's mission to develop next-generation precision molecules and provides a contact form for stakeholders who wish to stay informed about its progress. Beyond the information available on its official website and basic corporate registry data, specific details about the company's founding, leadership, ownership structure, and full pipeline are not provided in the available evidence. The company is identified in public records as a business entity located in Carlsbad, United States. As a clinical-stage biotechnology company, its activities center on research and development rather than commercialized products, and its near-term milestones would typically involve clinical trial progress for its lead candidate.

Tyra Biosciences is a biotechnology company based in Carlsbad, California, United States. Publicly available information identifies it as a company in Carlsbad, and its official website describes its work as developing next-generation precision molecules. The company's primary disclosed clinical focus is an oral drug candidate called dabogratinib, which it is advancing in clinical studies for skeletal dysplasia and urologic cancers. The available evidence does not specify the company's founding date, founders, or early corporate history. What is clear is that Tyra Biosciences operates as a clinical-stage precision-medicine developer, a category of biotechnology company that designs targeted therapies intended to address specific disease mechanisms. Its lead program, oral dabogratinib, spans two therapeutic areas: skeletal dysplasia, which encompasses rare genetic conditions affecting bone and cartilage, and urologic cancers, which include cancers of the urinary tract and related organs. The company maintains a public website at tyra.bio, where it communicates its mission and invites stakeholders to receive updates on its clinical studies. This outreach suggests an active clinical development phase, with the company seeking to keep patients, clinicians, and investors informed about trial progress. Because the supplied evidence is limited to the official website homepage and basic registry data, further details about Tyra Biosciences' financing, partnerships, leadership, or pipeline beyond dabogratinib are not documented here. The company's history to date is therefore best understood as that of an emerging precision-oncology and rare-disease biotech focused on advancing its lead oral candidate through clinical trials.

Developer of next-generation precision molecules for rare skeletal dysplasia and urologic cancers.

• Oral dabogratinib

  Clinical-stage oral drug candidate being studied for skeletal dysplasia and urologic cancers.

1. 1Tyra Biosciences | Next-Generation Precision Medicinestyra.bio
2. 2Tyra Biosciences - Wikidatawikidata.org
3. 3Tyra Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sharesprnewswire.com